CRISPR Therapeutics AGCRSPNASDAQ
Loading
SG&A Expenses Over TimeStable
Percentile Rank64
3Y CAGR-10.5%
5Y CAGR-3.0%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-10.5%/yr
vs +20.7%/yr prior
5Y CAGR
-3.0%/yr
Recent deceleration
Acceleration
-31.2pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$73.54M+0.8%
2024$72.98M-4.2%
2023$76.16M-25.7%
2022$102.46M+2.8%
2021$99.69M+16.3%
2020$85.75M+35.1%
2019$63.49M+31.5%
2018$48.29M+34.7%
2017$35.84M+15.4%
2016$31.06M-